Showing 7551-7560 of 8649 results for "".
- ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat DED & Ocular Inflammationhttps://modernod.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/ProtoKinetix announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP. For the development of this drug for DED to date the company has completed:
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- Study: Glaucoma May Be More than Just an Issue of Eye Pressurehttps://modernod.com/news/study-glaucoma-may-be-more-than-just-an-issue-of-eye-pressure/2479078/A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show. Led by researchers at NYU Grossman School of Medicine, the study centers on the watery fluid inside the eye on which its function depends. Fluid pr
- Moderna’s COVID-19 Vaccine Shows Sustained Protection at Six Monthshttps://modernod.com/news/modernas-covid-19-vaccine-shows-sustained-protection-at-six-months/2479079/Moderna announced longer-term data Tuesday from the phase 3 trial used to support authorizations of its coronavirus vaccine mRNA-1272, saying the vaccine continues to show more than 90% efficacy against cases of COVID-19, including 95% protection from severe disease, a median 6 months after the s
- World Council of Optometry Passes Resolution Calling for a Standard of Care for Myopia Managementhttps://modernod.com/news/world-council-of-optometry-passes-resolution-calling-for-a-standard-of-care-for-myopia-management/2479073/The World Council of Optometry (WCO) Board of Directors unanimously approved a resolution advising optometrists to incorporate a standard of care for myopia management within their practices. “Myopia is increasing at an alarming rate, as are the risks for vision impairment associated with
- LION Eye Group to Develop New Retail Stores in New Yorkhttps://modernod.com/news/lion-eye-group-to-develop-new-retail-stores-in-new-york/2479074/New York-based LION Eye Group announced its intent to move forward with “LION Express,” a state-of-the art, eyewear focused, retail optometric store. The group is currently scouting locations in Garden City, Huntington,
- NEI Joins Call for Standardization of Ophthalmic Imaging Deviceshttps://modernod.com/news/nei-joins-call-for-standardization-of-ophthalmic-imaging-devices/2479064/The National Eye Institute (NEI), part of the National Institutes of Health, is joining the American Academy of Ophthalmology (AAO) and others in calling for imaging device makers to standardize their data formatting. Such standardization is expected to enable comm
- Computer Model Fosters Potential Improvements to ‘Bionic Eye’ Technologyhttps://modernod.com/news/computer-model-fosters-potential-improvements-to-bionic-eye-technology/2479063/There are millions of people who face the loss of their eyesight from degenerative eye diseases. The genetic disorder retinitis pigmentosa alone affects 1 in 4,000 people worldwide. Today, there is technology available to offer partial eyesight to people with that syndrome. The Argus II, the worl
- Essilor to Present New Results for its Stellest Lens for Children With Myopiahttps://modernod.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day,1 according to
- Systematic Review of Standalone iStent Trabecular Micro-Bypass Glaucoma Surgeryhttps://modernod.com/news/systematic-review-of-standalone-istent-trabecular-micro-bypass-glaucoma-surgery/2479056/A new meta-analysis of the iStent and iStent inject (Glaukos) found that standalone trabecular micro-bypass glaucoma surgery with the devices is associated with clinically relevant reductions in intraocular pressure. The focus of the study, which was published in the Journal of Glaucom